Screener
Mineralys Therapeutics, Inc. MLYS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
FAQ
- What is Mineralys Therapeutics, Inc.'s EPS (diluted)?
- Mineralys Therapeutics, Inc. (MLYS) reported EPS (diluted) of -$0.47 in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Mineralys Therapeutics, Inc.'s EPS (diluted) increased by 40.5% year-over-year, from -$0.79 to -$0.47.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s EPS (diluted) has grown at a -26.2% compound annual growth rate (CAGR), from -$5.78 to -$2.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Mineralys Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude